Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignancies
Article
[키워드] active malignancy
analyzed
antibodies
antibody
association
Asymptomatic
booster
booster dose
booster vaccination
Cancer
coronavirus
coronavirus disease
Coronavirus disease-19
Course
COVID-19
COVID-19 infection
COVID-19 vaccination
COVID-19-related death
death
decrease
detectable
diagnosed
died
effective
eliminated
Hematologic malignancy
high-risk population
humoral
Humoral immunity
immunization
incidence of COVID-19
Infection
initial
lack
less
lowest
lymphoma
malignancy
monoclonal antibody
occurred
outcome
outcomes
Patient
postvaccination
promote
Prophylactic
proportion
reduced
response to vaccination
revaccination
risk
risk of COVID-19
Seroconversion
seroconversion rate
Serologic response
seronegative
suggested
the patient
therapy
treated
Treatment
undetectable
vaccination
Vaccine
[DOI] 10.1002/cncr.34354 PMC 바로가기
[DOI] 10.1002/cncr.34354 PMC 바로가기